A data analysis comparing growth rates of US inflation and Medicare Part B drug prices (2015-2022) reveals that average sales price (ASP) has grown slower than inflation, making it a more transparent and relevant metric than list prices for evaluating medical spending trends.
Magnolia Market Access analyzed a potential sliding fee scale policy, adjusting patient cost-sharing for 340B-dispensed drugs, to understand implications on out-of-pocket costs for 340B patients.
Magnolia Market Access analyzed a potential sliding fee scale policy, adjusting patient cost-sharing for 340B-dispensed drugs, to understand implications on out-of-pocket costs for 340B patients.
A small-size pharmaceutical company was interested in using real-world evidence to compare adherence between two formulations of an oral oncology treatment for Multiple Myeloma (MM).
Magnolia Market Access has just released its fourth IRA Payer Insights Survey. This chartbook provides an overview of findings from the 34 payers and actuaries surveyed and interviewed regarding the future Medicare Drug Price Netoriation Program, Part D Redesign, and the Medicare Prescription Payment Program.
A new, oral formulation of an existing infused product offered better adherence and less waste, but it was uncertain if these benefits would change payer, provider, and patient pain points or critical success factors for the product’s pricing strategy.
A company wanted to understand if user perceptions of the hub had improved after implementing changes. Patients and providers previously expressed dissatisfaction with services offered by company’s hub (confusing process, eligibility criteria, who to communicate with), and they recently relaunched the program with enhanced services, a customer portal, and redefined roles for client facing teams.
AMCP Spring 2024 Silver Poster.
Magnolia engaged pharmacy directors, medical directors, and actuaries at health plans and PBMs to understand how payers are designing their plan offerings and adjusting their formularies in the coming years.
Magnolia Market Access surveyed medical and pharmacy directors at health plans and pharmacy benefit managers to understand how the IRA will affect the future of the pharmaceutical industry and access to care.